Based on our 100-year history with respiratory
therapies, PARI recognizes that the future of
aerosol therapies lies in the combined
optimization of drug and device. This idea is
the basis of the PARI Pharma.
PARI Pharma
is part of the global network of
PARI
Worldwide companies. The focus of PARI Pharma is
the optimization of Advanced Aerosol
Delivery platforms, such as eFlow®,
with new liquid medications. The
goal is to produce extremely short
and effective treatments that lead
to increased patient compliance,
disease symptom control, and a
better quality of life for patients.
By optimizing drug and device under one roof, we
increase the speed of development for
our pharmaceutical partners. Our projects include
the re-invention of existing medications and
the development of new medications. We are
currently working on therapies for both the
lower (pulmonary) and upper (sinus, nasal)
respiratory pathways with targeted and systemic
treatments.
Our Core Competencies include:
aerosol science
►
business development ►
chemistry
►
engineering
►
fluid dynamics
►
industrial
design
►
intellectual property
►
manufacturing
►
pharmaceutical development
►
pharmacology
►
physics
►
project management ►
quality management ►
regulatory support
PARI Pharma continues PARI's tradition of developing high
quality, technologically-advanced devices that
can be mass produced for worldwide nebulized
treatments. |
